Literature DB >> 18371165

Radioisotope synovectomy with rhenium186 in haemophilic synovitis for elbows, ankles and shoulders.

K Kavakli1, S Aydogdu, M Taner, Y Duman, C Balkan, D Y Karapinar, G Saydam, K Capaci, A Oktay.   

Abstract

We have performed 221 radioisotope synovectomy (RS) in more than 150 children and young adults with haemophilia, age ranging 3-30 years (mean 15) in Ege Hemophilia Center, Izmir, Turkey for last 7 years. We always preferred to use Yttrium 90 (Y(90)) for knees; however, since 2005, we started using rhenium 186 (Re(186)) for medium-sized joints with respect to safety. In this article, we have evaluated long-term experience ranging from 6 months to 3 years (mean 18 months) with Re(186) for elbows (n = 35), ankles (n = 26) and shoulders (n = 2) in total of 63 RS procedures for 49 patients. Their age range was 3-30 years and mean age was 15.5. Two mCi of Re(186) intra-articularly injected for treating target joints and chronical synovitis. After RS, joint bleedings were decreased for all patients. The best results were obtained for all joints in patients with grade-II synovitis as like earlier experience with Y(90). Excellent rates (no bleeding) were observed in grade-II synovitis in 81% and 46% for elbows vs. 86% and 57% for ankles after 6 months and after 1 year follow-up of patients, respectively. In grade-III synovitis, excellent rates were 53% and 25% for elbows and 44% and 29% for ankles, respectively. In five joints for five patients, repeated injections were needed for better outcome. No adverse events such as radioisotope leakage, local inflamatory reactions or malignancy development were observed during and after RS. For medium-sized joints, RS with Re(186) seems to be either effective or safe treatment method. Our results confirm those previously published by others on the value of Re(186) synoviorthesis in medium-sized joints in haemophilia patients. After this experience, we changed our protocol and we use Re(186) for all medium-sized joints for treating chronical synovitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18371165     DOI: 10.1111/j.1365-2516.2008.01691.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  4 in total

1.  The use of 185 MBq and 740 MBq of 153-samarium hydroxyapatite for knee synovectomy in haemophilia.

Authors:  J U M Calegaro; J Machado; R G Furtado; J S C de Almeida; A V P de Vasconcelos; M F de Barboza; A P de Paula
Journal:  Haemophilia       Date:  2013-12-16       Impact factor: 4.287

2.  Treatment with radiosynoviorthesis in hemophilic patients with and without inhibitor.

Authors:  Mario Edgar Tena-Sanabria; Yoriko Fabiola Rojas-Sato; José Carlos Castañeda-Resendiz; Gabriela Fuentes-Herrera; Félix Alejandro Álvarez-Martínez; Yureni Iraí Tena-Gonzalez; Juan Carlos Núñez-Enríquez
Journal:  BMC Pediatr       Date:  2020-04-20       Impact factor: 2.125

3.  The use of radiosynovectomy in patients with juvenile idiopathic arthritis. Assessment of treatment efficacy and safety.

Authors:  Agnieszka Gazda; Jarosław Ćwikła; Beata Kołodziejczyk; Izabela Szczygielska; Elżbieta Hernik; Piotr Gietka; Lidia Rutkowska-Sak
Journal:  Reumatologia       Date:  2021-08-26

4.  The efficacy of magnetic resonance imaging and x-ray in the evaluation of response to radiosynovectomy in patients with hemophilic arthropathy.

Authors:  Tamer Ozülker; Filiz Ozülker; Esin Derin; Mehmet Altun; Gönül Aydoğan; Emine Türkkan; Müjdat Adaş; Murat Tonbul; Tevfik Ozpaçacı; Funda Sezgin; Hülya Değirmenci
Journal:  Mol Imaging Radionucl Ther       Date:  2011-08-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.